alexa Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group.
Microbiology

Microbiology

Journal of Antivirals & Antiretrovirals

Author(s): Thase ME

Abstract Share this page

Abstract BACKGROUND: This was a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of once-daily venlafaxine extended release (XR) in out-patients with DSM-IV major depression. METHOD: Patients were randomly assigned to venlafaxine XR (75-225 mg) once daily or placebo for up to 8 weeks. The primary efficacy variables were the 21-item Hamilton Rating Scale for Depression (HAM-D) total score and HAM-D depressed mood item, the Montgomery-Asberg Depression Rating Scale (MADRS) total scores, and the Clinical Global Impressions (CGI) Severity scale. Data were analyzed on a modified intent-to-treat basis using the last-observation-carried-forward method. RESULTS: Venlafaxine XR (N = 91) was significantly more effective than placebo (N = 100) beginning at Week 2 on the CGI Severity scale, at Week 3 on the HAM-D depressed mood item, and at Week 4 on the HAM-D and MADRS; this superiority was maintained through Week 8. The most common treatment-emergent adverse events associated with venlafaxine XR were nausea, insomnia, and somnolence. The incidence of nausea was highest during the first week, decreased by 50\% during the second week, and was comparable to that of placebo from Week 3 onward. CONCLUSION: These results demonstrate that venlafaxine XR is an effective and well-tolerated treatment of major depression.
This article was published in J Clin Psychiatry and referenced in Journal of Antivirals & Antiretrovirals

Relevant Expert PPTs

  • Limin Chen
    An 18- Gene Signature Predicting Treatment Response to Interferon in Patients Chronically Infected with Hepatitis C Virus
    PPT Version | PDF Version
  • Sudha Srivastava
    Novel Inhibitor by Modifying Oseltamivir Based on Neuraminidase Structure for Treating Drug-Resistant H5N1 Virus Using Molecular Docking NMR and DSC Methods
    PPT Version | PDF Version

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords